化合物PD180970 T23128

Product Introduction
Bioactivity


英文名: PD180970

描述: PD180970 是一种 Bcr-Abl 抑制剂，对于 p210Bcr-Abl、Src 和 Kit 的自磷酸化，IC50 分别为 5 nM、0.8 nM 和 50 nM。 PD180970 可用于慢性粒细胞白血病的研究。

体外活性: In K562 cells, PD180970 (0.5 μM) induces apoptosis and causes cell death. The IC50 values are 170, 80, and 80 nM for the tyrosine phosphorylation of p210Bcr-Abl, Gab2, and CrkL. PD180970 significantly inhibits the purified recombinant Abl tyrosine kinase activity with an IC50 of 2.2 nM[1]. In the human K562 CML cells, PD180970 inhibits the activity of Stat5 DNA-binding with an IC50 of 5 nM[2].

体内活性: In Male C57BL/6J mice injected with MPTP, intraperitonial injection of PD180970 (5 mg/kg) decreased number of activated microglia on activation by MPTP and reduces the Iba1 expression intensity in activated microglia[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 90.0 mg/mL (209.7 mM)


关键字: PD180970 | PD-180970

相关产品: Rebastinib | Berbamine dihydrochloride | Vamotinib | KW-2449 | AT9283 | Adaphostin | GMB-475 | Agerafenib | AD57 | SIAIS100 TFA

相关库: Anti-Cancer Metabolism Compound Library | Bioactive Compounds Library Max | Kinase Inhibitor Library | Inhibitor Library | Cytoskeletal Signaling Pathway Compound Library | Tyrosine Kinase Inhibitor Library | Bioactive Compound Library

化合物PD180970 T23128信息由TargetMol中国为您提供，如您想了解更多关于化合物PD180970 T23128报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途